Slows clinical progression at 76 weeks for those with low/medium tau and the combined low/medium and high tau pathology population
While Leqembi did help reduce mental decline compared with placebo, the drug has been linked to two deaths from brain bleeds
Improvement in global cognition seen for patients with Alzheimer disease/MCI, but no effects seen for healthy individuals, other patient populations
Greater effect seen for patients aged 70 years and older at time of bacillus Calmette-Guerin vaccination
Patients who received 2 or 3 mg of Rexulti had significant improvements in agitation scores compared with patients taking a placebo
Proof-of-concept study is 'encouraging' for repurposing insomnia drug, authors say
Findings show importance of decomposing the traditional awareness score
In creating the database, the goal is to provide something that can 'improve applicability and generalizability of findings'
Later age at menopause and hormone therapy nonuse also associated with higher regional tau
Social isolation may be a modifiable risk factor for preventing Alzheimer disease-related dementias, authors say